Collaboration that improves treatment options for sickle cell patients in the UK

In exclusive partnership with Theravia, we are driving sustainable growth and improving nationwide access to Siklos® across the UK. Through targeted national key account management, deep NHS and haematology network expertise, and strong KOL advocacy, we are supporting specialist centres and strengthening treatment pathways for patients living with sickle cell disease. This case study explores how a focused commercial strategy, combined with disease insight and stakeholder engagement, is expanding access and delivering measurable impact in a complex healthcare environment.

In partnership with Theravia – driving growth and access for Siklos® in the UK

As the exclusive distribution partner for Theravia in the United Kingdom, we are committed to driving sustainable growth and expanding patient access to Siklos® nationwide. Our collaboration is built on aligned marketing and sales strategies that reflect both overarching business objectives and the specific needs of local NHS stakeholders, clinicians, and patients.

‍

A targeted national approach

At the core of our strategy is dedicated National Key Account Management. Through a Specialist Multi-Channel Account Manager, we actively engage more than 40 key hospitals and specialist sickle cell disease (SCD) centres across the UK. This focused, relationship-driven approach ensures consistent engagement, tailored communication, and meaningful partnerships with decision-makers and clinical teams.

‍

Deep disease and market expertise

Our work is underpinned by robust disease expertise. We conduct comprehensive patient journey and population mapping to understand local dynamics and unmet needs. Detailed KOL and reference centre mapping allows us to collaborate with leading experts and centres of excellence. With in-depth knowledge of NHS frameworks and haematology networks, combined with thorough competitor analysis, we ensure our strategies are both informed and impactful.

‍

Building brand awareness and visibility

We maintain a strong and visible presence across key national and international conferences, NHS educational events, training days, regional haematology committee meetings, and peer-to-peer forums. These platforms enable us to share clinical insights, reinforce the value of Siklos®, and engage directly with healthcare professionals who are central to improving outcomes in SCD.

‍

Advocacy through partnership

Advocacy plays a critical role in driving adoption and confidence. Through strong partnerships and KOL endorsement, we support informed decision-making and help champion best practice in SCD management. Our collaborative approach strengthens credibility and fosters long-term trust within the haematology community.

‍

Expanding access for patients

Ultimately, our partnership is focused on one goal: improving access to better treatment options for people living with sickle cell disease across the UK. By combining strategic account management, clinical expertise, brand visibility, and stakeholder advocacy, we are helping to ensure that appropriate patients can access Siklos® as part of their care pathway—supporting better outcomes nationwide.

‍

Read Next

Commercialisation of Desferal® in Brazil, in partnership with Mitem Pharma

In partnership with Mitem Pharma, we are strengthening access to essential haematology treatments across Brazil. The successful transfer of Desferal® from Novartis, combined with a dedicated haematology sales force and a locally tailored commercial strategy, has reinforced our growing portfolio in the region.

Improving access to life-changing treatment for sickle cell patients in Saudi Arabia

As part of our long-term strategic partnership with Theravia, we have successfully expanded Siklos® into Saudi Arabia. This case study highlights how careful market preparation, KOL engagement, and national account management can accelerate access to essential treatments in a new territory.